Overview

A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain

Status:
Unknown status
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This study aims to determine the safety and utility of using 5-Aminolevulinic Acid (ALA) in removing malignant brain tumors during surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Legacy Health System
Collaborator:
DUSA Pharmaceuticals, Inc.
Treatments:
Aminolevulinic Acid